These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18360826)

  • 1. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
    Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
    Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
    Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
    Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
    J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
    Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
    Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
    Hopkins-Donaldson S; Cathomas R; Simões-Wüst AP; Kurtz S; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Int J Cancer; 2003 Aug; 106(2):160-6. PubMed ID: 12800189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
    Varin E; Denoyelle C; Brotin E; Meryet-Figuière M; Giffard F; Abeilard E; Goux D; Gauduchon P; Icard P; Poulain L
    Carcinogenesis; 2010 Jun; 31(6):984-93. PubMed ID: 20142415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
    Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM
    J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
    Opitz I; Sigrist B; Hillinger S; Lardinois D; Stahel R; Weder W; Hopkins-Donaldson S
    Lung Cancer; 2007 Jun; 56(3):327-36. PubMed ID: 17383050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.
    Masui T; Hosotani R; Ito D; Kami K; Koizumi M; Mori T; Toyoda E; Nakajima S; Miyamoto Y; Fujimoto K; Doi R
    Surgery; 2006 Aug; 140(2):149-60. PubMed ID: 16904964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
    Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
    Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
    Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma.
    Cao X; Rodarte C; Zhang L; Morgan CD; Littlejohn J; Smythe WR
    Cancer Biol Ther; 2007 Feb; 6(2):246-52. PubMed ID: 17224645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
    Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
    Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
    Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
    BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
    Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
    BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
    Smythe WR; Mohuiddin I; Ozveran M; Cao XX
    J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.